Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


SuperGen withdraws Orathecin EU application

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

SuperGen has withdrawn its European marketing authorization application for its oral pancreatic cancer agent Orathecin (rubitecan), the firm announces Jan. 20. The oral camptothecin's future appears to hinge on an ongoing U.S. Phase II trial looking at Orathecin in combination with gemcitabine in the first-line pancreatic cancer setting. "SuperGen intends to make a decision on future development or the alternative disposition of Orathecin based on a review of the interim results of this trial, expected to occur during the first half of 2006," the firm says. In January 2005, SuperGen withdrew an NDA seeking a monotherapy claim for Orathecin, citing FDA's focus on statistical versus clinical benefit (1Pharmaceutical Approvals Monthly January 2005, p. 39). The firm had expected a more favorable stance from EMEA, but the European agency raised several "major concerns" and said it "considers that the overall risks of the product were higher than the benefits to patients"...

You may also be interested in...

SuperGen Will Pursue Orathecin As Combo Therapy Following NDA Withdrawal

SuperGen may develop Orathecin as combo therapy following NDA withdrawal. Firm withdrew application in advance of anticipated negative action from FDA. SuperGen is moving ahead with a combination trial with gemcitabine

Reimbursement Questions Jeopardize Hillrom/Bardy Merger

Hillrom is reconsidering its planned $375m acquisition of Bardy Diagnostics because of Novitas' plan to cut Medicare reimbursement for extended cardiac monitoring. Bardy is suing to complete the deal.

Boston Scientific Pays More Than $1Bn For Lumenis’ Surgical Laser Business

Lumenis’ surgical business includes the MOSES laser system for minimally invasive urology surgery which will complement Boston Scientific’s LithoVue ureteroscope.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts